Agios Pharmaceuticals withdraws application

Agios Pharmaceuticals Inc. (Nasdaq: AGIO) withdrew its investigational new drug application for AG-519 and will no longer develop its second pyruvate kinase-R activator. The stock price plummeted $10.86 to close at $45.08.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.